Company profile
Verastem, Inc.
NASDAQ:VSTMBiotechnology: Pharmaceutical Preparations
Drug pipeline (6)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Avutometinib Potassium | approved | — | 0 | — |
| DEFACTINIB HYDROCHLORIDE | approved | — | 0 | — |
| DEFACTINIB | phase2 | — | 3 | completed, terminated |
| Avutometinib | phase1 | — | 1 | no active trials |
| VS-4718 | phase1 | — | 2 | terminated, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (27)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02372227 | phase1 | terminated | 2015-01-01 | 2015-10-01 | Verastem, Inc. | A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma |
| NCT07020221 | phase1_2 | recruiting | 2025-06-24 | 2028-12-01 | Verastem, Inc. | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors |
| NCT07659795 | phase2 | recruiting | 2026-07-28 | 2027-06-01 | Verastem, Inc. | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer |
| NCT07659782 | phase2 | recruiting | 2026-07-22 | 2027-06-01 | Verastem, Inc. | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer |
| NCT07644559 | phase2 | recruiting | 2026-06-16 | 2027-06-01 | Verastem, Inc. | A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| NDA 219616 | NDA | VERASTEM INC | ||||
Loading… | ||||||